Table 1.

Rate of change of FEV1 categorized by beta-agonist subtype in patients not receiving sirolimus

Beta-agonist typeFEV1 rate of change, mean percent predicted per year ± SE
None−1.470 ± 0.070 (1,594 visits)
Beta-agonist−1.939 ± 0.118 (962 visits)
P < 0.001
None−1.304 ± 0.082 (1,594 visits)
Short-acting−1.677 ± 0.238 (391 visits)
Both short-acting and long-acting−0.783 ± 0.255 (349 visits)
Long-acting−2.443 ± 0.391 (222 visits)
N vs. SP = 0.1291
N vs. SLP = 0.0457
N vs. LP = 0.0040
S vs. SLP = 0.0095
S vs. LP = 0.0908
SL vs. LP = 0.0003
  • With statistical correction, significant P values are those less than 0.0083. L, long-acting beta-agonist; N, no beta agonist; S, short-acting beta-agonist; SL, short- and long-acting beta-agonists.